文献速递前列腺癌

联合应用IsoPSA与前列腺影像报告和数据系统评分或有助于优化PSA升高患者的前列腺穿刺决策

Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.
PubMed 文献 · Urology · 2023-03-24

IsoPSA比值≥6.0(OR 5.06,P=.015)与PI-RADS 4-5(OR 6.37,P<.001)均为csPCa的显著预测因子,二者联合AUC为0.83(P<.001)。作者认为MRI阴性或不确定且IsoPSA比值≤6时csPCa预测概率<5%,或可据此省略穿刺。

要点

  • IsoPSA比值≥6.0与PI-RADS 4-5均为csPCa的显著预测因子。
  • 二者联合预测csPCa的AUC为0.83(P<.001)。
  • PI-RADS 1-3且IsoPSA比值≤6时csPCa预测概率<5%。

核心结论

  • PI-RADS与IsoPSA比值联合可能有助于优化穿刺决策。
  • 在本队列中,MRI阴性或不确定且IsoPSA比值低时,csPCa预测概率低至可考虑省略穿刺。

研究设计与样本

  • 采用多变量逻辑回归识别穿刺csPCa(即GG≥2)的预测因子,并基于IsoPSA与不同PI-RADS评分生成csPCa的预测概率。

主要发现

  • IsoPSA比值升高(定义为≥6.0)是csPCa的显著预测因子(OR 5.06,P=.015)。
  • PI-RADS 4-5是csPCa的显著预测因子(OR 6.37,P<.001)。
  • IsoPSA比值升高联合PI-RADS 4-5病变的AUC最高(AUC 0.83,P<.001)。
  • MRI阴性或不确定(PI-RADS 1-3)且IsoPSA比值低(≤6)时,csPCa预测概率<5%。

关键数值与推荐

  • IsoPSA比值升高定义为≥6.0。
  • csPCa定义为GG≥2。
  • MRI阴性或不确定定义为PI-RADS 1-3。
  • IsoPSA比值低定义为≤6。

临床怎么用

  • 作者认为,在本队列中MRI阴性或不确定且IsoPSA比值低时,csPCa预测概率<5%,可考虑省略穿刺。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess how IsoPSA, a structure-based serum assay which has been prospectively validated in detecting clinically significant prostate cancer (csPCa), can help the biopsy decision process when combined with the prostate imaging reporting and data systems (PI-RADS). MATERIALS AND METHODS: This was a single-center retrospective review of prospectively collected data on patients receiving IsoPSA testing for elevated PSA (>4.0ng/mL). Patients were included if they had received an IsoPSA test and prostate MRI within 1 year of IsoPSA testing, and subsequently underwent prostate biopsy. Multivariable logistic regression was used to identify predictors of (csPCa, ie, GG ≥ 2) on biopsy. Predictive probabilities for csPCa at biopsy were generated using IsoPSA and various PI-RADS scores. RESULTS: Two hundred and 7 patients were included. Twenty-two percent had csPCa. Elevated IsoPSA ratio (defined as ≥6.0) (OR: 5.06, P = .015) and a PI-RADS 4-5 (OR: 6.37, P <.001) were significant predictors of csPCa. The combination of elevated IsoPSA ratio and PI-RADS 4-5 lesion had the highest area under the curve (AUC) (AUC: 0.83, P <.001). The predicted probability of csPCa when a patient had a negative or equivocal MRI (PI-RADS 1-3) and a low IsoPSA ratio (≤6) was <5%. CONCLUSION: The combination of PI-RADS with IsoPSA ratios may help refine the biopsy decision-making process. In our cohort, a negative or equivocal MRI with a low IsoPSA may provide a low enough predicted probability to omit biopsy in such patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Benidir T, Lone Z, Wood A, et al. Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA. Urology. 2023. PMID: 36965817. doi:10.1016/j.urology.2023.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。